Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination
Savara Inc. and PARI have been granted a European patent for the combination of Savara’s investigational therapy, MOLBREEVI, and PARI’s eFlow Nebulizer System. The patent provides protection until March 2043. MOLBREEVI is being developed for autoimmune pulmonary alveolar proteinosis (PAP) and has received several regulatory designations. Upon approval, the eFlow Nebulizer System will be marketed as the Vespera Nebulizer System for use with MOLBREEVI.
Savara Inc. and PARI have been granted a European patent (No. 4 496 611) covering the combination of Savara’s investigational therapy, MOLBREEVI, and PARI’s optimized eFlow® Nebulizer System for aerosolizing the liquid solution. The patent provides protection for the drug-device combination through March 2043. MOLBREEVI, which is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), has received several regulatory designations in the US, EU, and UK. Upon approval, the eFlow® Nebulizer System is expected to be marketed as the Vespera® Nebulizer System for use with MOLBREEVI. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202230500) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
